Novartis India has declared encouraging results for 3QFY02. Net profits have leapfrogged by more than 100% on a back of sharp spurt in operating margins. However, the growth in topline has slowed down considerably with just 2% growth in the concerned quarter. Subsequent to completion of the demerger of its agribusiness and amalgamation of Ciba CKD Biochem, the company has recast prior period results. The results are thus comparable on a year to year basis.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
This is third quarter in succession that Novartis has reported a positive surprise on the operating margins. The improvement in margins seems to be on the back of new product introductions, a sharp drop in purchase price of pharma products and closure of its loss making ciba vision business. Novartis incurred a one time VRS cost of Rs 18.8 m during the quarter. Further, other expenditure included Rs 16.6 m provision towards dimunition in the value of investments in US 64. Both the above items being extra-ordinary in nature, we have not taken them into consideration while calculating operating margins.
% of sales
Purchase of finished goods
The segmental information provided by the company discloses some interesting facts. While margins and sales growth in the pharma business have remained more or less stable, there has been a sharp improvement in margins of its consumer health care business (OTC). The operating margins in this business has jumped from 4.5% for the first half, to 23.9% in the third quarter. Though on a small base, sales also seem to be growing at a fast clip in this business.
Table Showing Segmentwise operating margins
9 m FY02
Sales (Rs m)
Sales (Rs m)
Animal Healthcare Business
*- Profit before interest and tax
At the current market price of Rs 236, the stock trades at 12x its annualised earnings for 9m FY02. The benefits of the restructuring excerise undertaken by the company is evident in the current results. Going forward, it seems that though the company would be able to maintain its margins due to its presence in niche speciality segments, the topline is clearly dependent on new product introductions. The stock is likely to see upside due to positive surprise on the margin front.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407